A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)

被引：14

作者：

Powles, T. B. ^{[1
]}

van der Heijden, M. S. ^{[2
]}

Castellano Gauna, D. ^{[3
]}

Loriot, Y. ^{[4
]}

Galsky, M. D. ^{[5
]}

Petrylak, D. P. ^{[6
]}

Ogawa, O. ^{[7
]}

Park, S. H. ^{[8
]}

Necchi, A. ^{[9
]}

Lee, J-L. ^{[10
]}

De Giorgi, U. ^{[11
]}

Boegemann, M. ^{[12
]}

Bamias, A. ^{[13
]}

Fay, A. P. ^{[14
]}

Duran, I. ^{[15
]}

Angra, N. ^{[16
]}

Gupta, A. K. ^{[16
]}

He, P. ^{[16
]}

Levin, W. ^{[16
]}

Bellmunt, J. ^{[17
]}

机构：

[1] Queen Mary Univ London, Barts Canc Inst, Dept Med Oncol, London, England

[2] Netherlands Canc Inst, Med Oncol Dept, Amsterdam, Netherlands

[3] Univ Hosp 12 Octubre, Med Oncol Dept, Madrid, Spain

[4] Univ Paris Sud, Canc Med Dept, Inst Gustave Roussy, Villejuif, France

[5] Mt Sinai Hosp, Tisch Canc Inst, New York, NY 10029 USA

[6] Yale Univ, Sch Med, Med Oncol Dept, Smilow Canc Ctr, New Heaven, CT USA

[7] Kyoto Univ, Dept Med Oncol, Kyoto, Japan

[8] Samsung Med Ctr, Dept Med, Seoul, South Korea

[9] Ist Nazl Tumori Milano Fdn IRCCS, Med Oncol Dept, Milan, Italy

[10] Univ Ulsan, Coll Med, Med Oncol Dept, Asan Med Ctr, Seoul, South Korea

[11] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Med Oncol Dept, Meldola, Italy

[12] Univ Klinikum Munster, Med Oncol Dept, Munster, Germany

[13] Natl & Kapodistrian Univ Athens, Dept Oncol, Alexandra Hosp, Athens, Attiki, Greece

[14] Hosp Sao Lucas PUCRS, Grp Oncoclin, Med Oncol Dept, Porto Alegre, RS, Brazil

[15] Hosp Univ Marques de Valdecilla, Med Oncol, Santander, Spain

[16] AstraZeneca, Med Oncol Dept, Gaithersburg, MD USA

[17] Dana Farber Canc Inst, Med Oncol Dept, Boston, MA 02115 USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.769

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

697O

引用

页码：S550 / S551

页数：2